In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses the success a myeloma patient can have with pomalidomide, even if that patient has not had a response with other drugs in the iMiD category.

Previous Post
When will the first monoclonal antibody be approved?
Next Post
The Value of Annual PET/CT as a Screening Tool for Myeloma Patients

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.